Optimal resting heart rate and ascites-related death in patients with cirrhosis and ascites using nonselective beta-blockers (ORCA)
dc.contributor.author | Mingpun W. | |
dc.contributor.author | Sobhonslidsuk A. | |
dc.contributor.author | Chumnumwat S. | |
dc.contributor.other | Mahidol University | |
dc.date.accessioned | 2023-11-29T18:02:35Z | |
dc.date.available | 2023-11-29T18:02:35Z | |
dc.date.issued | 2023-01-01 | |
dc.description.abstract | Nonselective beta-blockers (NSBBs) may exacerbate ascites by impairing cardiac function. This study evaluated the impact of achieving a heart rate target of 55–60 beats per minute (bpm) on ascites-related death and complications from worsening ascites in patients with cirrhosis and diuretic-responsive ascites using NSBBs. A retrospective study was conducted at the Faculty of Medicine Ramathibodi Hospital, Mahidol University (2012–2022) and analyzed patients with cirrhosis and diuretic-responsive ascites using NSBBs (propranolol/carvedilol) for variceal bleeding prophylaxis. The outcomes were incidence of ascites-related death and complications from worsening ascites, comparing the achievable target group (heart rate 55–60 bpm) and the unachievable target group (heart rate >60 bpm). A total of 206 patients were included in the study, with a median follow-up time of 20 months. The patients were divided into an achievable target group (n = 75, median heart rate = 58.0 bpm) and an unachievable target group (n = 131, median heart rate = 73.6 bpm). Propranolol was the most used NSBB (95.1%). The adjusted hazard ratio (HR) for ascites-related death from spontaneous bacterial peritonitis (SBP) or refractory ascites (RA) or hepatorenal syndrome (HRS) or hepatic encephalopathy (HE) showed no difference between the groups (adjusted HR 0.59 [0.23–1.54]; p = 0.28). Additionally, no significant difference was found in the incidence of complications between groups, including SBP, RA, HRS, and HE. Achieving a heart rate target of 55–60 bpm with NSBBs for variceal bleeding prophylaxis is safe in patients with diuretic-responsive ascites and cirrhosis. | |
dc.identifier.citation | Clinical and Translational Science (2023) | |
dc.identifier.doi | 10.1111/cts.13681 | |
dc.identifier.eissn | 17528062 | |
dc.identifier.issn | 17528054 | |
dc.identifier.pmid | 37950532 | |
dc.identifier.scopus | 2-s2.0-85177579293 | |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/91251 | |
dc.rights.holder | SCOPUS | |
dc.subject | Neuroscience | |
dc.title | Optimal resting heart rate and ascites-related death in patients with cirrhosis and ascites using nonselective beta-blockers (ORCA) | |
dc.type | Article | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85177579293&origin=inward | |
oaire.citation.title | Clinical and Translational Science | |
oairecerif.author.affiliation | Ramathibodi Hospital | |
oairecerif.author.affiliation | Mahidol University | |
oairecerif.author.affiliation | Chiang Mai University |